Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUDITH L WHITE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1316940018
CMS profile
14471
Location
KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$51.76

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $51.76 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $51.76 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUDITH L WHITE

NPI 1316940018 · CMS profile ID 14471

Allopathic & Osteopathic Physicians / Internal Medicine

KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316940018?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316940018?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316940018?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1316940018?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $51.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.0905/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892637921 CMS
ABBVIE INC. $19.4004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892637919 CMS
ABBVIE INC. $14.2701/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892637917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.12 28
PY2021 $2,163.83 6
PY2022 $51.76 3
PY2024 $1,672.68 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $640,741.74 27
PY2024 Principal investigator $267,189.88 19
PY2023 Recipient $98.80 1
PY2023 Principal investigator $96,720.88 105
PY2022 Recipient $85.00 1
PY2022 Principal investigator $1,700,193.53 16,257
PY2021 Recipient $242.50 1
PY2021 Principal investigator $910,699.42 50
PY2020 Recipient $1,336.87 14
PY2020 Principal investigator $850,450.68 67
PY2019 Principal investigator $1,175,554.95 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

106 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $1,182.48 07/31/2023 Non-covered Recipient Entity
NEW HORIZON RESEARCH CENTER
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038122157
Principal investigator 1 Eli Lilly and Company $56,958.00 06/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038079131
Principal investigator 1 ModernaTX, Inc. $163.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941079
Principal investigator 1 ModernaTX, Inc. $163.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941087
Principal investigator 1 ModernaTX, Inc. $163.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941095
Principal investigator 1 ModernaTX, Inc. $163.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941103
Principal investigator 1 ModernaTX, Inc. $957.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941109
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941117
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941123
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941131
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941141
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941149
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941155
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941163
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941171
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941181
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941189
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941197
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941207
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941215
Principal investigator 1 ModernaTX, Inc. $67.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941223
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941761
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941767
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941775
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941783
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941789
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941797
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941805
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941813
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941821
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941829
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941841
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041941851
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942051
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942059
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942067
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942077
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942087
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942097
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942107
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942115
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942123
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942131
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942139
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942147
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942155
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942163
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942171
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942179
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942187
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942195
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942203
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942211
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942219
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942227
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942241
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942247
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942255
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942263
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942271
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942279
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942287
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942295
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942303
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942311
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942321
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942327
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942335
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942343
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942351
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942359
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942367
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942377
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942385
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942393
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942399
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942407
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942413
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942425
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942429
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942437
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942445
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942455
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942461
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942469
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942477
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942485
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942493
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942501
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942511
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942519
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942527
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942535
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942543
Principal investigator 1 ModernaTX, Inc. $706.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942549
Principal investigator 1 ModernaTX, Inc. $470.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942559
Principal investigator 1 ModernaTX, Inc. $470.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942565
Principal investigator 1 ModernaTX, Inc. $470.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942573
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942581
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942589
Principal investigator 1 ModernaTX, Inc. $100.00 05/30/2023 Non-covered Recipient Entity
AES Orlando (DRS)
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041942599
Principal investigator 1 Eli Lilly and Company $67.00 05/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038079931
Recipient Eli Lilly and Company $98.80 04/28/2023 Covered Recipient Physician RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038052433
Principal investigator 1 ABBVIE INC. $1,000.00 03/22/2023 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (AURORA) No dispute reported 06/30/2026 998375467
Principal investigator 1 ABBVIE INC. $3,247.40 02/13/2023 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (AURORA) No dispute reported 06/30/2026 998370479
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $187.00 01/05/2023 Non-covered Recipient Entity
Synexus
Phase IIB in NASH mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1027455045